Ascendis Pharma A/S (ASND)
NMS · Healthcare · Biotechnology
$218.06
+1.14%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$14.30B
Shares Outstanding
65.6M
P/S (TTM)
16.5x
P/E (TTM)
29.5x
Exchange
NMS
Currency
USD
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 158.0M | 213.6M | 247.5M | 246.6M |
| Gross Profit | 126.6M | 191.3M | 223.9M | 229.1M |
| Operating Income | -53.0M | 11.0M | 6.4M | 24.8M |
| Net Income | -38.9M | -61.0M | -33.6M | 629.3M |
| Diluted EPS | $-0.82 | $-1.00 | $-0.55 | $9.75 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 51.2M | 266.7M | 363.6M | 720.1M |
| Gross Profit | 39.0M | 222.3M | 319.4M | 625.2M |
| Operating Income | -561.8M | -455.5M | -278.8M | -136.3M |
| Net Income | -583.2M | -481.4M | -378.1M | -228.0M |
| Diluted EPS | $-10.40 | $-8.55 | $-6.53 | $-3.76 |